Contipro

What Contipro does

Contipro a.s. is a privately-held Czech pharmaceutical and biotechnology company founded in 1990 and headquartered in Dolní Dobrouč. The company specializes in the research, development, and production of hyaluronic acid (HA) and HA-based products, operating across pharmaceutical active ingredients, medical devices, cosmetic raw materials, dietary supplements, veterinary applications, and nanofiber production equipment. Nearly half of its 101-250 employees work in R&D, supported by state-of-the-art laboratories spanning several thousand square meters, and the company states it is among the world's leaders in HA research and production.

Core technology centers on biotechnological production of high-purity sodium hyaluronate via bacterial fermentation of Streptococcus zooepidemicus, free of animal-derived materials and pathogens, with molecular weight options spanning 7 kDa to 2,300 kDa. The proprietary 4SPIN platform produces organized nanofibers from HA and other polymers through electrostatic spinning at semi-industrial scale, with built-in safety features. Manufacturing operates under GMP (ICH Q7) certification, has been FDA-audited, holds Certificates of Suitability to the European Pharmacopoeia from EDQM, and has a Drug Master File filed with the FDA. The company holds multiple patents and utility models and launches 2-4 new products per year.

Contipro generates revenue through B2B sales of pharmaceutical-grade sodium hyaluronate and cosmetic raw materials to manufacturers globally, finished medical devices (including the Sicalm HA dental tamponade), branded consumer products under the Geloren joint-health line sold via a dedicated e-commerce storefront, and hardware sales of 4SPIN nanofiber equipment to research institutions and industrial customers. Distribution is handled through direct B2B sales and international distribution networks serving Europe, North America, and Asia-Pacific, with quote-based pricing and multi-year contracts on the API side. Revenue is not publicly disclosed. R&D is supported by an extensive portfolio of EU and Czech government grants funding active projects in nanobiotechnology, biomaterials, stem cells, neurodegenerative disease treatments, wound healing devices, and new HA forms.

Name

Contipro

Legal name

Contipro a.s.

Website

https://contipro.cz

Company type

Private

Founded year

1990

Operating status

Operating

Headcount range

101–250 employees

Short description

Contipro is a Czech pharmaceutical and biotechnology company founded in 1990 that researches, produces, and sells hyaluronic acid-based products including pharmaceutical active ingredients, medical devices, cosmetic ingredients, dietary supplements (Geloren), veterinary products, and proprietary nanofiber production equipment (4SPIN).

Ownership category

akta.pro rank

Product category

Pharmaceutical Biotechnology

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Bio-based Pharmaceuticals, Nutraceuticals & Specialty Bioactives (EUAAAIAK)

akta.pro secondary industries

Wound Healing & Skin Regeneration (advanced dressings, skin substitutes) (HLAAAGAG), Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE), Nutraceuticals & Functional Ingredients for Animal Diets (Probiotics, Omega-3, Joint, GI) (HLAMAHAH)

Keywords

• Hyaluronic acid production
• Pharmaceutical ingredients
• Biotechnology manufacturing
• Nanofiber technology
• Cosmetic raw materials

Headquarters

HQ city

Dolni Dobrouc

HQ country

Czechia

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical Active Ingredients (API): Sale of high-purity hyaluronic acid as active pharmaceutical ingredient to pharmaceutical manufacturers. Products include sodium hyaluronate in various molecular weights (HMW 250-2300 kDa, LMW 7-250 kDa) for pharmaceutical applications.
2. Medical Devices: Development and sale of medical devices based on hyaluronic acid including wound healing products, ophthalmic surgery applications, and dental products like Sicalm HA.
3. Branded Consumer Products: Sale of branded products including Geloren dietary supplements for joint health and veterinary products under the same brand.
4. Cosmetic Raw Materials: Supply of anti-aging substances including hyaluronic acid, peptides, and other cosmetic ingredients to cosmetics manufacturers.
5. Nanotechnology Equipment: Sale of 4SPIN devices for nanofiber production to research institutions and industrial customers.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Contipro biotechnologically produces pharmaceutical-grade hyaluronic acid (sodium hyaluronate) via bacterial fermentation of Streptococcus zooepidemicus and sells it as an active pharmaceutical ingredient to drug manufacturers. The company also develops and sells medical devices based on hyaluronic acid (wound healing, dental), anti-aging cosmetic raw materials, the proprietary 4SPIN nanofiber production equipment, the Geloren branded joint nutrition supplement line for humans and animals, and customized hyaluronan derivatives and specialities.

Product overview

Contipro is a Czech pharmaceutical and biotechnology company (founded 1990) specializing in hyaluronic acid research and production. The company operates on three pillars: active pharmaceutical ingredients (API), modern technical equipment, and innovative final products. Its product portfolio includes pharmaceutical-grade sodium hyaluronate (produced via bacterial fermentation), the proprietary 4SPIN nanofiber production technology, medical devices including Sicalm HA dental products, the Geloren food supplement and veterinary product line, anti-aging cosmetic ingredients, and custom hyaluronan derivatives. Research and development is central to the business, with approximately half of employees dedicated to R&D activities in state-of-the-art laboratories.

Differentiator

Problem solved

Functional benefit

Brands

• Geloren: Joint health dietary supplement product line for humans and animals
• 4SPIN
• Fybich
• Institut

Products and services

• Sodium Hyaluronate (Pharmaceutical Grade)

Quantifiable outcome

• Products stable for 36 months at recommended storage conditions (2-8°C)
• +1 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

One partnership is on record.

• Family Business Network CzechmoderateOthersContipro became a proud member of Family Business Network Czech in 2023, connecting with other family-owned businesses in the region.

Scale indicators6 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• Novonesis (formerly Novozymes): Global biotechnology leader in industrial enzymes and microbial fermentation, with growing exposure to biopolymers including hyaluronic acid via partnerships. Comparable in fermentation process technology and biotech manufacturing capabilities, though not a direct HA competitor.
• Crown Laboratories: US-based specialty skincare and aesthetics company with a portfolio including HA-based dermal fillers and skincare products. Comparable as a downstream consumer of HA technology focused on aesthetics and dermatology end-markets.

Broad incumbents

• Galderma: Global dermatology-focused pharma with a strong aesthetics and skincare portfolio, including injectable HA-based fillers. Comparable as a downstream consumer of HA technology in dermatology and aesthetics, though not a primary HA manufacturer.
• Evonik Industries: Global specialty chemicals giant with a portfolio that includes HA production for medical and cosmetic applications via its Health Care business line. Comparable as a fermentation-based HA supplier but operating at much broader portfolio and scale.
• LG Chem (Life Sciences): Korean chemical conglomerate with a Life Sciences division producing HA APIs and biosimilar products for global markets. Comparable as a large-scale fermentation-based HA manufacturer supplying pharmaceutical and cosmetic markets.

Direct peers

• Seikagaku Corporation: Japanese specialty pharma built around glycosaminoglycan chemistry (including hyaluronic acid) for joint injection therapies and ophthalmic viscosurgical devices. Comparable in API science, molecular-weight specialization, and indication focus.
• Fidia Farmaceutici: Italian specialty pharma focused on HA-based products for joint health (viscosupplementation), ophthalmology, and wound care. Comparable as a vertically integrated HA-based pharmaceutical and medical device company selling into overlapping indications.
• Anika Therapeutics: US-listed specialty medical device company developing HA-based intra-articular, ophthalmic, and regenerative products (e.g., Monovisc, Cingal, Hyalofast). Comparable as a hyaluronic-acid-based therapeutic and regenerative medicine company.
• Bloomage Biotech: The world's largest hyaluronic acid producer, with end-to-end coverage from raw material fermentation to branded skincare and medical aesthetics products. Directly comparable to Contipro across pharma-grade HA APIs, medical-aesthetics applications, and cosmetic ingredients.

Others

• Sanofi (Genzyme/Synvisc franchise): Global pharmaceutical major that markets HA-based intra-articular injection products (e.g., Synvisc/Synvisc-One) through its specialty care franchise. Comparable as a downstream competitor in HA-based joint therapies, though operating as a broad pharmaceutical incumbent rather than a HA specialist.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xtwitter.com/contipro
• YouTubeyoutube.com/user/ContiproGroup
• Facebookfacebook.com/Contipro
• LinkedInlinkedin.com/company/contipro
• Instagraminstagram.com/contipro_official

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Contipro